This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Orphan drug commercialization in Europe - Using France as gateway to Europe

Orphan drug commercialization in Europe - Using France as gateway to Europe


It is often a challenge for small and medium-sized biopharmaceutical companies to bring their novel medicines to European patients. Although there is only one centralized approval for innovative drugs in Europe, each European Member State has its own pricing and reimbursement system. This interactive workshop will focus on how small and medium-sized enterprises can best bring their rare disease therapies to European patients. 

Moderator: Paul Neveux, Associate Value and Access, France/Europe at HealthEcon, Basel

  • François Houÿes –  Information & Access to Therapies, Director & Health Policy Ad visor, EURORDIS-Rare Diseases Europe 
  • Pierre Levy – Associate Professor in Economics, Universite Paris-Dauphine 
  • Frederic Prince – General Manager, France, bluebird bio